RECCE PHARMACEUTICALS LTD — Director's Dealing 2021

Feb 24, 2021

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Recce Pharmaceuticals Ltd ( Company ) ACN 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Alan W Dunton
Date of last notice	11 December 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect Interest
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	Danerius, LLC
Date of change	22 February 2021
No. of securities held prior to change	70,000 Fully Paid Ordinary Shares
Class	Unlisted Options
Number acquired	1,125,000UnlistedOptions,eachexercisableat$1.56,expiring22February 2026
Number disposed	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

	Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	Nil cash consideration. Issue of UnlistedOptions as approved by shareholders atthe Annual General Meeting held on 30November 2020. Further details on theissue can be found in the Notice ofMeeting released to ASX on 30 October	Nil cash consideration. Issue of UnlistedOptions as approved by shareholders atthe Annual General Meeting held on 30November 2020. Further details on theissue can be found in the Notice ofMeeting released to ASX on 30 October	Nil cash consideration. Issue of UnlistedOptions as approved by shareholders atthe Annual General Meeting held on 30November 2020. Further details on theissue can be found in the Notice ofMeeting released to ASX on 30 October	Nil cash consideration. Issue of UnlistedOptions as approved by shareholders atthe Annual General Meeting held on 30November 2020. Further details on theissue can be found in the Notice ofMeeting released to ASX on 30 October
				2020.
	No of securi	ties held after chan		70000	Full Paid Ordinar S	ares
	.	g		,	y y
				1,125,0	00 Unlisted Options
	Nature of chanExample: on-marke	get trade, off-market trade, exercis	e of options,	Issue oshareh	f Unlisted Options as aolders at the Annu	pproved byal General
	issue of securities ubuy-back	nder dividend reinvestment plan	, participation in	Meetin	g held on 30 Novembe	r 2020

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to which interest related prior to	N/A
change
Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above	No
traded during a+closed period where prior written clearance was
required?
If so, was prior written clearance provided to allow the trade to	N/A
proceed during this period?
If prior written clearance was provided, on what date was this	N/A
provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011